Source:http://linkedlifedata.com/resource/pubmed/id/12912934
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2003-8-12
|
| pubmed:abstractText |
The CpG island methylator phenotype (CIMP) is observed in approximately 30% of colorectal cancer (CRC) cases and is characterized by the concurrent methylation of multiple CpG islands in tumor DNA. This phenotype (CIMP+) is more frequently observed in tumors with proximal location, microsatellite instability, and normal p53. Because it has previously been observed that each of these features is associated with a good survival benefit from 5-fluorouracil (5-FU)-based adjuvant chemotherapy, we investigated in the present study whether CIMP+ has independent predictive value. Experimental Design: CIMP+ status was evaluated in 103 stage III CRCs from patients treated with surgery alone and for an additional 103 cases from patients treated with surgery and adjuvant 5-FU-based chemotherapy. The two cohorts were randomly pair-matched for age, sex, and tumor site, and the median length of follow-up time was 39 months.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1078-0432
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2898-903
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12912934-Aged,
pubmed-meshheading:12912934-Antimetabolites, Antineoplastic,
pubmed-meshheading:12912934-Cohort Studies,
pubmed-meshheading:12912934-Colorectal Neoplasms,
pubmed-meshheading:12912934-CpG Islands,
pubmed-meshheading:12912934-DNA Methylation,
pubmed-meshheading:12912934-DNA Sequence, Unstable,
pubmed-meshheading:12912934-Female,
pubmed-meshheading:12912934-Fluorouracil,
pubmed-meshheading:12912934-Genes, p53,
pubmed-meshheading:12912934-Humans,
pubmed-meshheading:12912934-Male,
pubmed-meshheading:12912934-Middle Aged,
pubmed-meshheading:12912934-Multivariate Analysis,
pubmed-meshheading:12912934-Mutation,
pubmed-meshheading:12912934-Neoplasms,
pubmed-meshheading:12912934-Phenotype,
pubmed-meshheading:12912934-Prognosis,
pubmed-meshheading:12912934-Sensitivity and Specificity,
pubmed-meshheading:12912934-Time Factors
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
|
| pubmed:affiliation |
Departments of Surgery, University of Western Australia, Nedlands 6907, Australia.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|